Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business licensing deal

BoomRay Novartis Radioligand License Deal

Analysis based on 7 articles · First reported Sep 22, 2026 · Last updated Sep 22, 2026

Sentiment
15
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The deal is a modest positive for Novartis, adding a preclinical radioligand asset to its oncology pipeline at limited upfront cost, while validating the RLT space for investors. For privately held BoomRay, the up to USD 900 million in potential payments and royalties materially improves its funding outlook and credibility, though the undisclosed preclinical nature limits immediate market reaction.

biotechnology pharmaceuticals oncology

Boomray Pharmaceuticals Co., Ltd. announced on September 22, 2026 that it has entered into an exclusive global license agreement with Novartis Pharma AG for an undisclosed preclinical radioligand therapy (RLT) asset. Under the terms, BoomRay is eligible to receive up to USD 900 million, comprising an upfront payment plus development, regulatory, and sales milestone payments, with potential royalties on future global net sales. The deal pairs BoomRay's discovery and development capabilities in precision oncology radiopharmaceuticals with Novartis's global RLT expertise and commercial reach. BoomRay CEO Bo Shan called the agreement a significant milestone and validation of the company's discovery capabilities, while Shivam, Global Head of Oncology, Biomedical Research at Novartis, said the agreement complements Novartis's growing radioligand therapy portfolio and reflects its strategy of combining external innovation with internal R&D. BFC Partners acted as financial advisor to BoomRay. The asset remains preclinical and undisclosed, so near-term revenue impact is limited, but the transaction strengthens Novartis's oncology pipeline and provides BoomRay with substantial milestone-based funding and global development support.

100 Boomray Pharmaceuticals entered license agreement Novartis
priv
Licensor of the preclinical RLT asset; gains up to USD 900 million in upfront and milestone payments plus royalties, validating its discovery platform and improving its funding position.
Importance 95.0 Sentiment 70.0
stock
Licensee acquiring exclusive global rights to the RLT asset; expands its radioligand therapy portfolio and oncology pipeline with external innovation at limited upfront cost.
Importance 95.0 Sentiment 25.0
curr
Currency in which the up to USD 900 million in upfront, milestone, and royalty payments to BoomRay is denominated.
Importance 40.0 Sentiment 0.0
per
Chief Executive Officer of BoomRay who commented on the agreement as a significant milestone and validation of the company's capabilities.
Importance 30.0 Sentiment 10.0
per
Global Head of Oncology, Biomedical Research at Novartis, who stated the deal complements Novartis's radioligand therapy portfolio and external innovation strategy.
Importance 25.0 Sentiment 5.0
priv
Acted as financial advisor to BoomRay on the license agreement, a supporting advisory role with no direct market impact.
Importance 20.0 Sentiment 5.0
cnt
Home country of BoomRay, headquartered in Suzhou; the cross-border licensing deal highlights Chinese biotech innovation being licensed to a global pharmaceutical company.
Importance 15.0 Sentiment 5.0
Novartis related ↔ China
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.